» Articles » PMID: 34659879

Current Methodologies to Detect Circulating Tumor Cells: a Focus on Ovarian Cancer

Overview
Journal Am J Cancer Res
Specialty Oncology
Date 2021 Oct 18
PMID 34659879
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Identification of circulating tumor cells (CTC) in liquid biopsies opens a window of opportunities for the optimization of clinical management of oncologic patients. In ovarian cancer (OC), which involves atypical routes of metastatic spread, CTC analyses may also offer novel insights about the mechanisms behind malignant progression of the disease. However, current methodologies struggle to precisely define CTC number in the peripheral blood of OC patients, and the isolation of viable cells for further characterization is still challenging. The biggest limitation is the lack of methodological standardization for OC CTC detection, preventing comprehensive definition of their clinical potential required for the transfer to practice. Here we describe and compare methods for CTC analysis that have been implemented for OC thus far, discussing pros, cons and improvements needed. We identify biophysical separation approaches as optimal for CTC enrichment. On the other hand, the identification of specific tumor antigens or gene transcripts, despite displaying drawbacks related to tumor heterogeneity, still remains the best approach for OC CTC detection.

Citing Articles

Liquid Biopsy in the Clinical Management of Cancers.

Ho H, Chung K, Kan C, Wong S Int J Mol Sci. 2024; 25(16).

PMID: 39201281 PMC: 11354853. DOI: 10.3390/ijms25168594.


Facile preparation of a cost-effective platform based on ZnFeO nanomaterials for electrochemical cell detection.

Vajhadin F, Mazloum-Ardakani M, Hemati M, Moshtaghioun S Sci Rep. 2023; 13(1):4962.

PMID: 36973342 PMC: 10042879. DOI: 10.1038/s41598-023-31377-2.


Through the Looking Glass: Updated Insights on Ovarian Cancer Diagnostics.

Chakraborty S, Shenoy P, Mehrotra M, Phadte P, Singh P, Rekhi B Diagnostics (Basel). 2023; 13(4).

PMID: 36832201 PMC: 9955065. DOI: 10.3390/diagnostics13040713.


Protein Panel of Serum-Derived Small Extracellular Vesicles for the Screening and Diagnosis of Epithelial Ovarian Cancer.

Lai H, Guo Y, Tian L, Wu L, Li X, Yang Z Cancers (Basel). 2022; 14(15).

PMID: 35954383 PMC: 9367436. DOI: 10.3390/cancers14153719.


Assessment of a Size-Based Method for Enriching Circulating Tumour Cells in Colorectal Cancer.

Vasantharajan S, Barnett E, Gray E, McCall J, Rodger E, Eccles M Cancers (Basel). 2022; 14(14).

PMID: 35884509 PMC: 9319975. DOI: 10.3390/cancers14143446.

References
1.
He W, Kularatne S, Kalli K, Prendergast F, Amato R, Klee G . Quantitation of circulating tumor cells in blood samples from ovarian and prostate cancer patients using tumor-specific fluorescent ligands. Int J Cancer. 2008; 123(8):1968-73. PMC: 2778289. DOI: 10.1002/ijc.23717. View

2.
Wimberger P, Heubner M, Lindhofer H, Jager M, Kimmig R, Kasimir-Bauer S . Influence of catumaxomab on tumor cells in bone marrow and blood in ovarian cancer. Anticancer Res. 2009; 29(5):1787-91. View

3.
Deng G, Herrler M, Burgess D, Manna E, Krag D, Burke J . Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients. Breast Cancer Res. 2008; 10(4):R69. PMC: 2575542. DOI: 10.1186/bcr2131. View

4.
Farace F, Massard C, Vimond N, Drusch F, Jacques N, Billiot F . A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. Br J Cancer. 2011; 105(6):847-53. PMC: 3171010. DOI: 10.1038/bjc.2011.294. View

5.
Punnoose E, Atwal S, Spoerke J, Savage H, Pandita A, Yeh R . Molecular biomarker analyses using circulating tumor cells. PLoS One. 2010; 5(9):e12517. PMC: 2935889. DOI: 10.1371/journal.pone.0012517. View